Randomized trial · people
Thymosin Beta-4: 42-1260 mg into a vein well tolerated for 14 days
Checked against the paper Randomized trialPublished by PepVault
The takeaway
This is early human safety data for Thymosin Beta-4 given into a vein: it was well tolerated at these doses over 14 days, but this trial does not show that it treats anything.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2010
- Journal
- Ann N Y Acad Sci
What they tested
Is synthetic Thymosin Beta-4 given into a vein safe and tolerable in healthy people, and how does the body handle it across a range of doses?
How the study was done
A randomized, placebo-controlled early-stage trial in four groups of 10 healthy volunteers. Each group got one dose level (42, 140, 420 or 1260 mg) or placebo, a dummy infusion, first as a single dose into a vein and then, after a safety review, daily for 14 days.

What they found
Side effects were uncommon, and all were mild or moderate. No one had a serious adverse event, and no dose caused side effects bad enough to stop going higher. After a single dose, blood levels rose in step with the dose, and the half-life (how long it takes the body to clear half the drug) got longer at higher doses. The team judged the drug well tolerated across the full 42-1260 mg range, given once or daily for 14 days.
What it doesn’t show
This was a short safety study in healthy volunteers, with only 10 people per dose group. It did not test whether the drug helps the heart or any other condition, and it only covers doses given into a vein.
The paper
Ruff et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010.
The compound
More studies on Thymosin Beta-4
- Thymosin beta-4: no overall infarct area cut in 96 STEMI patientsRandomized trial · people · 2025
- Thymosin Beta-4: no serious adverse events in healthy volunteersRandomized trial · people · 2021
- Thymosin beta-4 in pregnant mice: longer newborns, more mature organsAnimal study · mice · 2021
- Thymosin beta-4 raised survival in mice with a coronavirus infectionAnimal study · mice · 2021
- Thymosin beta-4: more liver fibrosis in mice bred to make extra TB4Animal study · mice · 2017
- Thymosin beta-4 sped skin wound healing in diabetic and aged miceAnimal study · mice · 2003
- Every study on Thymosin Beta-4
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.